IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Integrated Engagement Services segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company serves pharmaceutical, biotechnology, device and diagnostic, and healthcare companies. IQVIA Holdings Inc. has a strategic alliance with MuleSoft, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
SymbolNYSE:IQV
CUSIPN/A
Phone919-998-2000
Debt
Debt-to-Equity Ratio1.40
Current Ratio1.13
Quick Ratio1.13
Price-To-Earnings
Trailing P/E Ratio28.62
Forward P/E Ratio24.36
P/E Growth1.86
Sales & Book Value
Annual Sales$9.74 billion
Price / Sales2.60
Cash Flow$9.4175 per share
Price / Cash13.27
Book Value$40.19 per share
Price / Book3.11
Profitability
EPS (Most Recent Fiscal Year)$4.36
Net Income$1.31 billion
Net Margins12.68%
Return on Equity13.51%
Return on Assets4.74%
Miscellaneous
Employees55,000
Outstanding Shares202,590,000
Market Cap$26.28 billion
Iqvia (NYSE:IQV) Frequently Asked Questions
What is Iqvia's stock symbol?
Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."
How were Iqvia's earnings last quarter?
Iqvia Holdings Inc (NYSE:IQV) announced its quarterly earnings data on Tuesday, July, 24th. The medical research company reported $1.29 EPS for the quarter, beating the Zacks' consensus estimate of $1.14 by $0.15. The medical research company earned $2.57 billion during the quarter, compared to the consensus estimate of $2.50 billion. Iqvia had a net margin of 12.68% and a return on equity of 13.51%. The business's revenue was up 9.0% on a year-over-year basis. View Iqvia's Earnings History.
When is Iqvia's next earnings date?
What guidance has Iqvia issued on next quarter's earnings?
Iqvia updated its FY18 earnings guidance on Tuesday, July, 24th. The company provided earnings per share (EPS) guidance of $5.35-5.55 for the period, compared to the Thomson Reuters consensus estimate of $5.40. The company issued revenue guidance of $10.25-10.4 billion, compared to the consensus revenue estimate of $10.24 billion.Iqvia also updated its Q3 guidance to $1.35-1.42 EPS.
What price target have analysts set for IQV?
19 equities research analysts have issued 1-year target prices for Iqvia's stock. Their forecasts range from $97.00 to $150.00. On average, they expect Iqvia's share price to reach $127.8333 in the next year. This suggests a possible upside of 2.3% from the stock's current price. View Analyst Price Targets for Iqvia.
What is the consensus analysts' recommendation for Iqvia?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 4 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.
Who are some of Iqvia's key competitors?
Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and Pieris Pharmaceuticals (PIRS).
Who are Iqvia's key executives?
Iqvia's management team includes the folowing people:
- Mr. Ari Bousbib, Chairman, CEO & Pres (Age 57)
- Mr. Michael R. McDonnell, Exec. VP & CFO (Age 54)
- Mr. W. Richard Staub III, Pres of R&D Solutions (Age 55)
- Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 57)
- Mr. James H. Erlinger III, Consultant (Age 60)
Who are Iqvia's major shareholders?
Iqvia's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Atalanta Sosnoff Capital LLC (0.20%), Bank of Montreal Can (0.08%), DNB Asset Management AS (0.05%), Barometer Capital Management Inc. (0.02%), Sumitomo Mitsui Asset Management Company LTD (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Iqvia stock include Ari Bousbib, Cpp Investment Board Private H, Dennis B Ph D Gillings, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Robert Parks and Ronald A Rittenmeyer. View Institutional Ownership Trends for Iqvia.
Which institutional investors are selling Iqvia stock?
IQV stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Fox Run Management L.L.C., Sumitomo Mitsui Asset Management Company LTD and Bremer Trust National Association. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Cpp Investment Board Private H, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Robert Parks and Ronald A Rittenmeyer. View Insider Buying and Selling for Iqvia.
Which institutional investors are buying Iqvia stock?
IQV stock was purchased by a variety of institutional investors in the last quarter, including Atalanta Sosnoff Capital LLC, Bank of Montreal Can, Barometer Capital Management Inc., Oliver Luxxe Assets LLC, Appleton Partners Inc. MA, NEXT Financial Group Inc, Contravisory Investment Management Inc. and Jaffetilchin Investment Partners LLC. View Insider Buying and Selling for Iqvia.
How do I buy shares of Iqvia?
Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iqvia's stock price today?
One share of IQV stock can currently be purchased for approximately $124.97.
How big of a company is Iqvia?
Iqvia has a market capitalization of $26.28 billion and generates $9.74 billion in revenue each year. The medical research company earns $1.31 billion in net income (profit) each year or $4.36 on an earnings per share basis. Iqvia employs 55,000 workers across the globe.
What is Iqvia's official website?
How can I contact Iqvia?
Iqvia's mailing address is 83 WOOSTER HEIGHTS ROAD, DANBURY CT, 06810. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]
MarketBeat Community Rating for Iqvia (NYSE IQV)
MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.
